Case report

Intolerance to and limitations of inspiratory muscle training in patients with advanced chronic obstructive pulmonary disease: A report of two cases

Yuji Yamamoto, Keisuke Miki*, Takanori Matsuki, Kiyoharu Fukushima, Yohei Oshitani, Hiroyuki Kagawa, Kazuyuki Tsujino, Kenji Yoshimura, Mari Miki, Hiroshi Kida

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan

ARTICLE INFO

Keywords:
Dyspnea
Respiratory muscles
Tachypnea
Underweight
Wasted ventilation

ABSTRACT

Inspiratory muscle training (IMT) has been attracting attention as one of the useful treatments in patients with chronic obstructive pulmonary disease (COPD). IMT is reportedly effective in most patients with COPD. However, little is known about the benefits of IMT, especially in patients with advanced COPD.

We reported two cases of COPD that received 12-week IMT to explore intolerance to and the limitations of IMT in advanced COPD. The effectiveness of IMT was evaluated using cardiopulmonary exercise testing (CPET), spirometry, and respiratory muscle strength testing before and after the training.

A 75-year-old man with normal body mass index (BMI) and forced expiratory volume in 1 s (FEV$_1$) of 1.63 L responded well to IMT, but a 78-year-old man with low BMI and FEV$_1$ of 0.83 L did not. In the responder, IMT resulted in increased minute ventilation (V'$_E$) and oxygen uptake at peak exercise in incremental load testing. Moreover, IMT increased endurance time in constant load testing and maximal inspiratory pressure. In both patients, breathing frequency (f$_R$) increased, but tidal volume and the inspiratory-expiratory ratio were not improved during exercise. Despite the high f$_R$ obtained after IMT, V'$_E$ at peak exercise did not increase and endurance time shortened in the non-responder.

In underweight patients with advanced COPD, IMT might lead to tachypnea and ventilatory inefficiency, which in turn might decrease exercise performance. Therefore, underweight patients with advanced COPD might be unable to tolerate IMT and should avoid receiving the training.

1. Introduction

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death [1] and a major disease associated with global morbidity and mortality [2]. Earlier studies reported that patients with COPD have a fundamental deficit of diaphragm fiber contractile force [3], which correlates with patient prognosis [4]. Hence, inspiratory muscle training (IMT) has been suggested as an effective non-pharmacological treatment, which can delay lung function deterioration by increasing inspiratory muscle strength and endurance [5].

However, IMT is reportedly not always effective in patients with COPD [6,7], and studies for assessing the precise clinical characteristics of patients responding to IMT have been published. As an approach to clarify the applicable criteria, the mechanism of how IMT improves exercise tolerance was hypothesized; IMT can increase type II fibers, shorten inspiratory time, lengthen expiratory time, and result in decreased dynamic hyperinflation [8–10]. Contrary to the hypothesis, however, Beaumont et al. reported that dynamic hyperinflation was not improved by IMT in patients with COPD [11]. From the observations abovementioned, IMT might change a breathing pattern other than dynamic hyperinflation and subsequently affect exercise tolerance in patients with COPD. Given that IMT activates inspiratory muscles and induces deeper breathing [12,13], we hypothesized that the improvement of exercise tolerance might be depended on the degree of ventilatory efficiency obtained from IMT.

We herein report two cases of COPD that received IMT for 12 weeks, suggesting the mechanism of how IMT works and showing that the utility appears to be limited.
2. Materials and methods

2.1. Patients and study design

Two Japanese patients with COPD who received IMT and were evaluated using CPET were included in the present study. The patients’ primary diagnoses of COPD were confirmed based on the Global Initiative for Chronic Obstructive Lung Disease definition and classification [14]. Both patients did not experience acute exacerbations of COPD, and their drug regimens were not changed at least for three months before IMT. Both patients received 12-week IMT, and its effectiveness was evaluated using cardiopulmonary exercise testing (CPET), spirometry, and respiratory muscle strength (RMS) testing before and after the training.

2.2. CPET

Symptom-limited exercise tests were performed using an electrically-braked cycle ergometer (CV–1000SS, Lode, Groningen, The Netherlands) using a CPET system (Marquette CASE series T 2001, GE Healthcare, Tokyo, Japan; Aero monitor AE 310S, Minato Medical Science Co., Ltd, Osaka, Japan) [15,16]. Incremental load testing was performed by increasing 10 W per 2 minutes. The starting workload of incremental load testing was 10 W. Moreover, constant load testing was performed at 70% of each patient’s maximum load obtained on incremental load testing at the baseline examination. Before CPET, patients were asked to exert maximum effort. CPET was performed until exhaustion without encouragement, especially during exercise. Both patients were asked to keep a cycle ergometer speed of about 60 rpm. Pre-exercise resting measurements were taken after reaching a steady-state period during at least 3 min of breathing through a mask. Measurements taken during CPET were as follows: minute ventilation (VE), oxygen uptake (VO2), carbon dioxide output (VCO2), breathing frequency (fR), inspiratory duty cycle (Ti/Ttot), tidal volume (VT), inspired oxygen concentration (FiO2), expired oxygen concentration (FeO2), dead space ventilation (VD/VT), lung volume (Vt), and respiratory muscle strength (RMS) were measured at rest according to the ERS standard [19]. Maximum inspiratory and expiratory mouth pressure were measured at rest according to the ERS statement [20]. Patients underwent the examination for four times, and the maximum value of respiratory pressure was adopted.

2.3. Spirometry

Both patients underwent spirometry using the CHESTAC 8800 spirometer (Chest MI, Inc., Tokyo, Japan) within 2 weeks before CPET according to the recommendations of the American Thoracic Society and the European Respiratory Society (ERS) [17]. Predicted vital capacity (VC), forced vital capacity (FVC), and forced expiration volume in 1 s (FEV1) were calculated according to the formula for Japanese patients developed by the Japanese Respiratory Society [18].

2.4. RMS testing

RMS was evaluated during maximal voluntary effort against occluded airways (Vitaropov KH-101; Chest Scientific Instruments Ltd; Westerham, United Kingdom) [19]. Maximum inspiratory and expiratory mouth pressure were measured at rest according to the ERS statement [20]. Patients underwent the examination for four times, and the maximum value of respiratory pressure was adopted.

2.5. IMT

Both patients received daily two sessions of IMT for 30 times each, 2 times a day, for 12 weeks, supervised by physiotherapists. IMT was performed using a threshold inspiratory muscle trainer (POWERbreathe®MedicPLUS; POWERbreathe International, Stratford Upon Avon, UK). The maximal inspiratory mouth pressure (MIP) was measured at the baseline examination by the previously mentioned method during the training program. The initial IMT resistance pressure was adjusted to 20% of the MIP. If possible, the load was increased by 5% every two weeks to maximal 50% for 12 weeks.

3. Results

3.1. Baseline characteristics

The patients’ baseline characteristics are shown in Table 1 and the following sentences. Notably, Case 2 was underweight and showed decreased VC, FVC, and FEV1/FVC ratio, which showed that Case 2 had mixed ventilatory defect.

Case 1. Responder to IMT

A 78-year-old man with COPD for 12 years had exertional dyspnea despite treatment with inhaled corticosteroids (ICS), a long-acting β2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA). He had a smoking history of 60 pack-years. His body mass index was BMI = 23.9 kg/m².

Case 2. Non-responder to IMT

A 78-year-old man with COPD for 12 years had exertional dyspnea despite LABA and LAMA treatment. He had a smoking history of 141 pack-years. His BMI was 17.0 kg/m².
Baseline characteristics.

| Parameter          | Case 1   | Case 2   |
|--------------------|----------|----------|
| Age, y             | 75       | 78       |
| Sex, male/female   | male     | male     |
| BMI, kg m\(^{-2}\) | 23.9     | 17.0     |
| Cigarette smoking, pack years | 60       | 141      |
| GOLD stage, I/II/III/IV | II       | III      |
| FEV\(_1\), L       | 1.63     | 0.83     |
| FEV\(_1\) % predicted | 60.8    | 34.3     |
| FVC, L             | 3.84     | 1.78     |
| FVC, % predicted   | 108.5    | 56.0     |
| FEV\(_1\)/FVC, %   | 42.4     | 46.6     |
| VC, L              | 4.08     | 1.94     |
| %VC, %             | 110.3    | 58.3     |
| IC, L              | 2.93     | 1.35     |
| Medications        | LAMA, LABA, ICS | LAMA, LABA |

3.2. Minute ventilation and oxygen uptake in incremental load testing after IMT

In Case 1, V\(_{E2}\) and the V\(_{E}\) at peak exercise increased from 893 mL/min to 939 mL/min and from 40.2 L/min to 44.8 L/min, respectively. In Case 2, however, both V\(_{E2}\) and V\(_{E}\) at peak exercise were not improved (V\(_{E2}\), from 313 mL/min to 277 mL/min; V\(_{E}\), from 21.4 L/min to 21.6 L/min) (Fig. 1A and B, and Table 2). The results showed that IMT contributed to the improved ventilation and the better exercise tolerance in Case 1, but not in Case 2.

3.3. Breathing pattern in incremental load testing after IMT

To assess the cause of treatment failure in Case 2, the breathing pattern in both patients was compared. In both patients, the FEV\(_1\) at peak exercise increased (Case 1, from 34/min to 44/min; Case 2, from 34/min to 39/min) (Fig. 1C). Moreover, the expiratory V\(_{T}\) (V\(_{T}\) ex) at peak exercise decreased in both patients (Fig. 1D), although FEV\(_1\) did not change significantly in both patients after IMT (Table 3). The results indicated that the breathing pattern in both patients became more rapid and shallower after IMT.

Regarding parameters of CPET related to tidal ventilation, Ti/Ttot was lower and V\(_{E}/V_{CO2}\) was higher in Case 2 than in Case 1 before IMT throughout the exercise. V\(_{E}/V_{CO2}\) increased during exercise in Case 2, but not in Case 1 (Fig. 1E and F). The results showed that the ventilatory efficiency in Case 2 was worse than that in Case 1 at pretreatment baseline. Moreover, the ventilatory efficiency declined during exercise only in Case 2.

Comparing the exertional patterns of Ti/Ttot and V\(_{E}/V_{CO2}\) before IMT with those after IMT, no significant changes were observed in both patients (Fig. 1E and F). Moreover, the difference between inspiratory V\(_{T}\) (V\(_{T}\) in) and V\(_{T}\) ex (V\(_{T}\) in−V\(_{T}\) ex) was not reduced significantly either in Case 1 or in Case 2 (Table 2). The results indicated that IMT seemed not to affect the ventilatory efficiency. In Case 1, furthermore, V\(_{E}/V_{T}\) increased slightly and P\(_{ET}CO2\) decreased after IMT during exercise (Fig. 1G and H). The results showed that, even in Case 1 that was considered a responder to IMT, the ventilatory efficiency declined after IMT.

3.4. Exercise endurance in constant load testing after IMT

In constant load testing, dyspnea intensity (Borg scale) and endurance time improved in Case 1. Notably, endurance time increased by 6.1 min, which was greater than the threshold for clinical significance: 100 s. In contrast, no change was observed in these measurements in Case 2 (Fig. 2). Other results of CPET are shown in Table 2. These results showed that IMT contributed to the improvement of exercise endurance only in Case 1.

3.5. MIP improved in both patients after IMT

MIP and maximum inspiratory mouth pressure (MIP) improved after IMT in Case 1 (Table 2). MIP in Case 2 improved from 56.7 cmH\(_{2}\)O to 63.5 cmH\(_{2}\)O. However, MIP was worsened from 96.2 cmH\(_{2}\)O to 75.2 cmH\(_{2}\)O.

4. Discussion

The present study highlights two major findings: 1) IMT might not improve the ventilatory efficiency in patients with advanced COPD; and 2) IMT might not be effective in underweight patients with advanced COPD when it induces tachypnea, reduces ventilatory efficiency, and fails to increase V\(_{E}\).

IMT has been recommended in patients with inspiratory muscle weakness [21]. IMT reportedly increases rib cage and neck muscle activation, and these muscle recruitment serve as a reserve to overcome increasing accessory muscle recruitment [12]. As the inspiratory muscles might be already trained [22], IMT is not effective in patients with COPD and high MIP (inspiratory muscle function > 60 cmH\(_{2}\)O) [6]. Moreover, earlier studies showed that IMT induced respiratory muscle strength and deeper breathing, reduced f\(_{R}\), and contributed to dyspnea relief and the improvement of exercise tolerance in patients with COPD and maintained BMI [13]. Hence, IMT had been hypothesized to improve dynamic hyperinflation by reinforcing inspiratory muscles [8–10].

However, as consistent with an earlier study [11], the present study showed that the resultant ventilatory condition after IMT was not due to the improvement of dynamic hyperinflation. Given no significant change of the V\(_{T}\) in−V\(_{T}\) ex, dynamic hyperinflation did not improve significantly after IMT even in Case 1. It has been reported in patients with COPD that dynamic hyperinflation correlated with the expiratory time ratio than with V\(_{E}\) and P\(_{ET}CO2\), and that the exertional increase of P\(_{ET}CO2\) was negatively correlated with the V\(_{E}/V_{CO2}\) slope [23,24]. Thus, the decrease of P\(_{ET}CO2\) and the increase of V\(_{E}\) in incremental load testing after IMT did not mean the improvement of dynamic hyperinflation in Case 1 (Fig. 1). From these observations, IMT might not improve dynamic hyperinflation even in patients with COPD who respond to IMT.

When IMT induces tachypnea and increased physiological dead space ventilation and fails to increase V\(_{E}\), IMT might not be effective in underweight patients with advanced COPD. The V\(_{E}\) and peak V\(_{E2}\) in incremental load testing and endurance time in constant load testing increased only in Case 1. Moreover, no significant changes of Ti/Ttot, V\(_{E}/V_{CO2}\), and V\(_{E}\) ex in both cases showed that IMT did not improve ventilatory efficiency in patients with advanced COPD. Given that V\(_{E}\) is calculated by the product of V\(_{T}\) ex and f\(_{R}\) and that IMT reduced V\(_{T}\) ex even in no significant range, the improvement of V\(_{E}\) was purely attributed to the increase of f\(_{R}\) in Case 1. In contrast, V\(_{E}\) did not change at peak exercise in Case 2, although f\(_{R}\) increased after IMT. These results suggest that V\(_{E}\) is not always improved by increasing f\(_{R}\) especially in patients with advanced COPD.

A possible explanation of the resultant ventilatory condition after IMT can be attributed to wasted ventilation, which is a phenomenon that excessive exercise ventilation due to tachypnea increases physiological dead space ventilation and decreases ventilatory efficiency [25]. As in Case 2, underweight patients with COPD sometimes show mixed ventilatory defect [26]. The mechanism of this mixed ventilatory defect would be that they become too hyperinflated to serve enough inspiratory volume, although they maximally use their expiratory muscles. Given that FVC decreased despite the increased MIP and that the MEP decreased even though the need for an expiratory drive was increased after IMT in Case 2 (Tables 2 and 3), expiratory muscles might not
overcome the obtained hyperinflation after IMT, and wasted ventilation might become severe. Therefore, IMT should not be recommended to underweight patients with advanced COPD who have severe findings such as extremely low FEV₁ and high MEP, prolonged expiration pattern during exercise, and decreased FVC. The present study is meaningful despite its scarcity of cases because CPET confirmed an exertional pathophysiological condition relevant to the evaluation and the clinical indications for IMT.

The present study had some limitations. First, this study included only two patients, and further large-scale studies are needed to validate the results of this study. Second, this study did not conduct inspiratory capacity maneuvers during exercise, and dynamic hyperinflation was not evaluated directly before and after IMT. Hence, studies for assessing the correlation between IMT and dynamic hyperinflation are needed.

In conclusion, we evaluated two patients with advanced COPD receiving IMT. When IMT induces wasted ventilation and decreases ventilatory efficiency, IMT may fail to increase $V'_E$ and to improve exercise tolerance. Therefore, underweight patients with advanced COPD who have exertional wasted ventilation at pretreatment may not respond to IMT. IMT might be appropriate only for patients who have maintained BMI and can tolerate tachypnea and achieve adequate ventilation during exercise. Further investigations are necessary to clarify the limitations of IMT and the threshold conditions that are relevant to IMT effectiveness.

**Funding sources**

None.
Table 2
Comparison of cardiopulmonary function between Case 1 and Case 2.

| Parameter                                  | Case 1 Before IMT | Case 1 After IMT | Case 2 Before IMT | Case 2 After IMT |
|--------------------------------------------|-------------------|------------------|-------------------|------------------|
| CPET, at peak exercise incremental load testing |                   |                  |                   |                  |
| \( V_{CO2} \), mL/min/kg                  | 14.0                                          | 14.1                                          | 7.5              | 6.3              |
| \( V_{CO2} \), mL/min                      | 893                                           | 939                                           | 313              | 277              |
| \( V_{E} \), L/min                        | 40.2                                          | 44.8                                          | 21.4             | 21.6             |
| \( f_{E} \), breath/min                    | 34                                            | 44                                            | 34               | 39               |
| \( V_t \), ex. ml                          | 1194                                          | 1129                                          | 625              | 559              |
| \( V_t \) in-\( V_t \) ex. ml              | 21                                            | 18                                            | 12               | 16               |
| Ti/Tot                                     | 0.41                                          | 0.41                                          | 0.32             | 0.34             |
| \( V_{E}/V_{CO2} \)                        | 40.9                                          | 47.6                                          | 76.9             | 80.2             |
| \( V_{E}/V_{L} \)                          | 0.40                                          | 0.43                                          | 0.48             | 0.48             |
| \( V_{E}/V_{CO2} \), mmHg                  | 38.5                                          | 35.6                                          | 28.1             | 24.4             |
| constant load testing                      |                   |                  |                   |                  |
| exercise time, s                           | 584                                          | 948                                          | 233              | 175              |
| Respiratory muscle strength                |                   |                  |                   |                  |
| MP, cmH\(_2\)O                            | 52.0                                          | 77.0                                          | 56.7             | 63.5             |
| MEF, cmH\(_2\)O                            | 69.2                                          | 92.0                                          | 96.2             | 75.2             |

Table 3
Spirometric parameters at rest before and after inspiratory muscle training.

| Parameter          | Case 1 Before IMT | Case 1 After IMT | Case 2 Before IMT | Case 2 After IMT |
|--------------------|-------------------|------------------|-------------------|------------------|
| FEV\(_1\), L       | 1.63              | 1.65             | 0.83              | 0.79             |
| FEV\(_1\), % predicted | 60.8              | 61.6             | 34.3              | 32.6             |
| FVC, L             | 3.84              | 3.81             | 1.78              | 1.42             |
| FVC, % predicted   | 108.5             | 107.6            | 56.0              | 44.7             |
| FEV\(_1\)/FVC, %    | 42.4              | 43.3             | 46.6              | 55.6             |
| VC, L              | 4.08              | 4.05             | 1.94              | 1.47             |
| %VC, %             | 110.3             | 109.5            | 58.3              | 44.1             |
| IC, L              | 2.93              | 3.03             | 1.35              | 1.13             |

FEV\(_1\), forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; IMT, inspiratory muscle training; VC, vital capacity.

Availability of data and materials

All data supporting our findings is contained within the manuscript.

Authors’ contributions

Y.Y. contributed to conceptualize and design the study, collect and analyze data of all patients, and wrote the manuscript. K.M. cared all patients, contributed to conceptualize and design the study, analyzed data, and revised the manuscript. T.M., K.F., Y.O., H.K., K.T., and K.Y. contributed to collect data of all patients and revise the manuscript. M. M. and H.K. contributed to the interpretation of data and the design of the study. All authors reviewed and approved the submission of the final manuscript.

Ethics approval and consent to participate

Ethical approval to report this case was not required.

Consent for publication

Written informed consent was obtained from the patients for publication of this report and any accompanying images.

Declaration of competing interest

The authors declare that there are no conflicts of interest associated with this manuscript.

Acknowledgements

The authors received no specific funding for the present study. The authors would like to thank Ms. S. Ito and Ms. S. Sakaguchi, and Mr. T. Uenishi for their help with the CPET measurements.

References

[1] World Health Organization, Disease burden and mortality estimates. https://www.who.int/healthinfo/global_burden_disease/estimates/en/ (Accessed 18 March 2020).
[2] GBD 2017 Causes of Death Collaborators, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet 392 (2018) 1736–1788, https://doi.org/10.1016/S0140-6736(18)32203-7.
[3] S. Levine, T. Nguyen, L.R. Kaiser, N.A. Rubinstein, G. Maislin, C. Gregory, et al., Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications, Am. J. Respir. Crit. Care Med. 168 (2003) 706–713, https://doi.org/10.1164/rccm.200209-1070OC.
[4] C.R. Borge, K.B. Hagen, A.M. Mengshoel, E. Omenaas, T. Moum, A.K. Wahl, Effects of controlled breathing exercises and respiratory muscle training in people with chronic obstructive pulmonary disease: results from evaluating the quality of evidence in systematic reviews, BMC Pulm. Med. 14 (2014) 184, https://doi.org/10.1186/1471-2466-14-184.
[5] F. Lüters, B. van Tol, G. Kwakkel, R. Gosselink, Effects of controlled inspiratory muscle training in patients with COPD: what is the evidence? Eur. Respir. J. 20 (2002) 570–576, https://doi.org/10.1183/09031936.02.00237402.
[6] M. Beaumont, P. Mialon, C. Le Ber-Moy, C. Lochon, L. Pérant, R. Pichon, et al., Inspiratory muscle training during pulmonary rehabilitation in chronic obstructive pulmonary disease: a randomized trial, Chron. Respir. Dis. 12 (2015) 305–312, https://doi.org/10.1177/1479972315594625.
[7] R. Gosselink, J. De Vos, S.P. van den Heuvel, J. Segers, M. Dcramer, G. Kwakkel, Impact of inspiratory muscle training in patients with COPD: what is the evidence? Eur. Respir. J. 37 (2011) 416–425, https://doi.org/10.1183/09031936.02.0037409.
[8] A. Ramirez-Sarmiento, M. Orozco-Levi, R. Guell, E. Barreiro, N. Hernandez, S. Mota, et al., Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomes, Am. J. Respir. Crit. Care Med. 166 (2002) 1491–1497, https://doi.org/10.1164/rccm.200202-075OC.
[9] C. Villafranca, G. Borzone, A. Leiva, C. Lisboa, Effect of inspiratory muscle training with an intermediate load on inspiratory power output in COPD, Eur. Respir. J. 11 (1998) 28–33, https://doi.org/10.1183/09031936.98.11010028.
[10] J.M. Marin, S.J. Carrizo, M. Gascon, A. Sanchez, B. Gallego, B.R. Celli, Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med. 166 (2002) 1491–1497, https://doi.org/10.1164/rccm.200202-075OC.
[11] M. Beaumont, P. Mialon, C. Le Ber, P. Le Mevel, L. Péran, O. Meurisse, et al., Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial, Eur. Respir. J. 51 (2018), https://doi.org/10.1183/13993003.01107-2017.

[12] A. Rodríguez, Z. Louvaris, S. Ischa, W. Janssens, F. Pitta, I. Vogiatzis, et al., Differences in respiratory muscle responses to hyperpnea or loaded breathing in COPD, Med. Sci. Sports Exerc. 52 (2020) 1126–1134, https://doi.org/10.1249/MSS.0000000000000222.

[13] D. Langer, C. Clavaglia, A. Faisal, K.A. Webb, J.A. Neder, R. Gosselink, et al., Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD, J. Appl. Physiol. 125 (2018) 381–392, https://doi.org/10.1152/japplphysiol.01078.2017.

[14] Global Initiative for Chronic Obstructive Lung Disease, Global strategy for prevention, diagnosis and management of COPD. https://goldcopd.org/. (Accessed 27 April 2020).

[15] L. Puente-Maestu, P. Palange, R. Casaburi, P. Laveneziana, F. Maltais, J.A. Neder, et al., Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement, Eur. Respir. J. 47 (2016) 429–460, https://doi.org/10.1183/13993003.00745-2015.

[16] T. Radtke, S. Crook, G. Kaltsakas, Z. Louvaris, D. Berton, D.S. Urquhart, et al., ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases, Eur. Respir. Rev. 28 (2019) 180101, https://doi.org/10.1183/16990607.0101-2018.

[17] M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, et al., Standardisation of spirometry, Eur. Respir. J. 26 (2005) 319–338, https://doi.org/10.1183/09031936.05.00034805.

[18] M. Kubota, H. Kobayashi, P.H. Quanjer, H. Omori, K. Tsutumi, M. Kanazawa, et al., Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values, Respir Investig 52 (2014) 242-250, https://doi.org/10.1016/j.resinv.2014.03.003.

[19] American Thoracic Society/European Respiratory Society, ATS/ERS Statement on respiratory muscle testing, Am. J. Respir. Crit. Care Med. 166 (2002) 518–624, https://doi.org/10.1164/rccm.166.4.518.

[20] M. Laveneziana, A. Albuquerque, A. Aliverti, T. Babb, E. Barreiro, M. Dres, et al., ERS statement on respiratory muscle testing at rest and during exercise, Eur. Respir. J. 53 (2019) 1801214, https://doi.org/10.1183/13993003.01214-2018.

[21] M.A. Spruit, S.J. Singh, C. Garvey, R. ZuWallack, L. Nici, C. Rochester, et al., An official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation, Am. J. Respir. Crit. Care Med. 188 (2013) e13-64, https://doi.org/10.1164/rccm.201309-16347L.

[22] W. Man, Maddocks Donaldson, Polkey M. Martolini, Muscle function in COPD: a complex interplay, COPD 523 (2012), https://doi.org/10.2147/COPD.S28247.

[23] C.B. Cooper, G.L. Calligaro, M.M. Quinn, P. Eshaghian, F. Coskun, M. Abraad, et al., Determinants of dynamic hyperinflation during metronome-paced tachypnea in COPD and normal subjects, Respir. Physiol. Neurobiol. 190 (2014) 76–80, https://doi.org/10.1016/j.resp.2013.08.002.

[24] E. Teopompi, P. Tzaní, M. Aiello, M.R. Gioia, E. Marangio, A. Chetta, Excess ventilation and ventilatory constraints during exercise in patients with chronic obstructive pulmonary disease, Respir. Physiol. Neurobiol. 197 (2014) 9–14, https://doi.org/10.1016/j.resp.2014.03.002.

[25] A.F. Elbehairy, C.E. Clavaglia, K.A. Webb, J.A. Guenette, D. Jensen, S.M. Mourad, et al., Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease. Implications for dyspnea and exercise intolerance, Am. J. Respir. Crit. Care Med. 191 (2015) 1384–1394, https://doi.org/10.1164/rccm.201501-0157OC.

[26] K. Miki, R. Maekura, N. Nagaya, S. Kitada, M. Miki, K. Yoshimura, et al., Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment, BMC Pulm. Med. 13 (2013) 37, https://doi.org/10.1186/1471-2466-13-37.